Monoclonal gammopathy of undetermined significance (MGUS) is one of the most prevalent premalignant conditions and carries approximately 1% annual risk of transformation to multiple myeloma or other lymphoproliferative disorders.
1 To date, 2 studies have reported shorter survival in clinically diagnosed US patients with MGUS compared with matched counterparts without MGUS. Nonetheless, these studies included predominantly White participants and did not adjust for comorbidities.
2,3 The observed shorter survival in patients with MGUS may be driven by underlying health conditions that led to incidental diagnosis of asymptomatic MGUS. We analyzed a nationally representative sample screened for MGUS to evaluate overall survival of populations with MGUS compared with the general US population.